Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients

European Journal of Clinical Investigation

Volumn 35, Issue 1, 2005, Pages 47-51

  Puccetti, Luca ^a   Sawamura, T ^b   Pasqui, A L ^a   Pastorelli, H ^a   Auteri, A ^a   Bruni, F ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Atherothrombosis; Atorvastatin; CD36; LOX 1; ox LDL

Indexed keywords

ATORVASTATIN; CD36 ANTIGEN; CITRULLINE; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; DIET; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; ANALYSIS OF VARIANCE; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD36; BLOOD PLATELETS; CITRULLINE; FEMALE; FLOW CYTOMETRY; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; P-SELECTIN; PLATELET ACTIVATION; PYRROLES; RECEPTORS, LDL; RECEPTORS, OXIDIZED LDL; SCAVENGER RECEPTORS, CLASS E;

EID: 13244289761     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01446.x     Document Type: Article

References (18)

1. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001;11:328-43.
2. Chen LY, Metha P, Metha JL. Oxidized LDL decreases 1-arginine uptake and nitric oxide syntase protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:1740-6.
3. 2+-ATPase. Cell Calcium 1996;19:453-8.
4. Retzer M, Siess W, Essler M. Midly oxidized low density lipoprotein induces platelet shape change via Rho-kinase-depenent phosphorylation of myosin light chain and moesin. FEBS Lett 2000;446:70-4.
5. 2. Arterioscler Thromb Vasc Biol 1995;15:1131-8.
6. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A et al. Time-dependent effect of statins on platelet function in hypercholesterolemic subjects. Eur J Clin Invest 2002;32:901-8.
7. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A et al. Platelet hyperactivuty after statin treatment discontinuation. Thomb Haemost 2003;90:476-82.
8. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-7.
9. Chen M, Kakutani M, Narudo T, Ueda M, Narumiya S, Masaki T et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun 2001;282:153-8.
10. Sakurai K, Sawamura T. Endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationship with oxidative stress. J Pharmacol Sci 2003;91:182-6.
11. Cominacini L, Fratta Pasini A, Garbin U, Pastorino A, Rigoni A, Nava C et al. The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol 2003;41:499-507.
12. Metha JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001;289:857-61.
13. Endemann G, Stanton LW, Maden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low-density lipoprotein. J Biol Chem 1993;268:11811-6.
14. Takahashi Y, Fuda H, Yanai H, Akita H, Shuping H, Chiba H et al. Significance of membrane glycoproteins in platelet interaction with oxidized low-density lipoprotein. Semin Thromb Haemost 1998;24:251-3.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 2001;285:2486-97.
16. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells. relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 2004;95:877-83.
17. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr 2003;133:3588-91.
18. Puccetti L, Bruni F, Bova G, Cercignani M, Palazzuoli A, Console E et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 2001;11:378-87.